Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Instituto do Cancer do Estado de São Paulo
University Hospital Tuebingen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
West China Hospital
West China Hospital
National Institutes of Health Clinical Center (CC)
Fudan University
M.D. Anderson Cancer Center
University College Cork
Rutgers, The State University of New Jersey
Rutgers, The State University of New Jersey
Sun Yat-sen University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University of Nebraska
Dana-Farber Cancer Institute
Vastra Gotaland Region
University Health Network, Toronto
Mayo Clinic
The Netherlands Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Washington University School of Medicine
Fudan University
Jonsson Comprehensive Cancer Center
Hospital Israelita Albert Einstein
UNICANCER
MedSIR
German Cancer Research Center
University College, London
Sun Yat-sen University
Institute of Cancer Research, United Kingdom
UNICANCER
Fudan University
Taproot Health
Shanghai Bovax Biotechnology Co., Ltd.
Travera Inc
The Netherlands Cancer Institute
University of Maryland, College Park
Universitaire Ziekenhuizen KU Leuven
The Affiliated Hospital of Qingdao University
SCG Cell Therapy Pte. Ltd.
M.D. Anderson Cancer Center
Gene Surgery LLC
University Medical Center Groningen
Shanghai Bovax Biotechnology Co., Ltd.
Oslo University Hospital